Agenus | AGEN - Equity Capital And Reserves


Agenus reported $-271.11M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Agenus USD -271.11M 3.03M Dec/2025
Amgen USD 9.19B 532M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Celldex Therapeutics USD 527.16M 71.2M Dec/2025
CSL USD 18.66B 2.75B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Glaxosmithkline GBP 22.06B 360M Dec/2025
Incyte USD 5.62B 455.37M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
J&J USD 81.19B 358M Mar/2026
Jiangsu Hengrui CNY 63.63B 2.35B Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Merck EUR 28.59B 344M Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -144.76M 17.01M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Veracyte USD 1.31B 51.91M Dec/2025